Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

118.63
-0.4200-0.35%
Pre-market: 118.890.2600+0.22%08:44 EDT
Volume:982.97K
Turnover:117.49M
Market Cap:9.86B
PE:-36.93
High:123.54
Open:119.58
Low:117.42
Close:119.05
52wk High:130.05
52wk Low:40.10
Shares:83.15M
Float Shares:64.87M
Volume Ratio:1.75
T/O Rate:1.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2122
EPS(LYR):-3.6900
ROE:-24.15%
ROA:-15.59%
PB:6.54
PE(LYR):-32.15

Loading ...

U.S. Stocks on the Move-american Express, Deckers, Q32 Bio

Reuters
·
Jul 13

RBC Downgrades Kymera Therapeutics to Sector Perform From Outperform, Lifts Price Target to $115 From $106, Keeps Speculative Risk

MT Newswires Live
·
Jul 13

Kymera Therapeutics Inc : RBC Cuts to Sector Perform from Outperform; Raises Target Price to $115 from $106

THOMSON REUTERS
·
Jul 13

Does Leadership Hire And Benchmark Additions Change The Bull Case For Kymera Therapeutics (KYMR)?

Simply Wall St.
·
Jul 11

Kymera CEO Nello Mainolfi Disposes of USD 5.95 Million in Common Shares

Reuters
·
Jul 08

Kymera Therapeutics Appoints Elizabeth Laws as SVP, Kt-621 Development Program Leader

Reuters
·
Jul 07

Kymera Therapeutics Appoints Elizabeth Laws, Ph.d., as Senior Vice President, Global Program Team Leader for Kt-621, First-in-class, Oral Stat6 Degrader

THOMSON REUTERS
·
Jul 07

German Pension Reform Turns Savers into Investors. That Will Fuel the Market. 13D Filings

Dow Jones
·
Jul 03

Kymera Therapeutics (KYMR) Stock Looks Fully Priced After A 405% Run

Simply Wall St.
·
Jul 03

Kymera CFO Bruce Jacobs Sells USD 8.67 Million in Common Shares

Reuters
·
Jul 03

Kymera Therapeutics (KYMR) Is Up 16.7% After KT-621 Trial Acceleration And Index Additions Has The Bull Case Changed?

Simply Wall St.
·
Jul 01

Kymera Therapeutics Director Bruce Booth Reports $57.91 Million Common Share Disposal

Reuters
·
Jul 01

Kymera Therapeutics is Maintained at Buy by B of a Securities

Dow Jones
·
Jun 30

Kymera Therapeutics price target raised to $125 from $110 at BofA

TIPRANKS
·
Jun 30

Kymera Therapeutics is Maintained at Buy by B. Riley Securities

Dow Jones
·
Jun 29

B. Riley Adjusts Kymera Therapeutics Price Target to $155 From $117, Maintains Buy Rating

MT Newswires Live
·
Jun 29

Kymera Therapeutics Inc : Truist Securities Raises Target Price to $136 from $116

THOMSON REUTERS
·
Jun 29

Major Investor Makes Dramatic Move in Kymera Therapeutics Holdings

TIPRANKS
·
Jun 27

BVF Partners Reports Kymera Therapeutics Share Disposal Worth $173.84 Million

Reuters
·
Jun 27

Movement Alert|Kymera Therapeutics Falls 7.48% in Regular Trading, Trading at $107.68

Market Focus
·
Jun 27